4-pregenen-11β-17-21-triol-3,20-dione derivatives

Patent metadata

Field	Value
Publication number	US-9433631-B2
Application number	US-201414533847-A
Country	US
Kind code	B2
Filing date	Nov 5, 2014
Priority date	Nov 11, 2011
Publication date	Sep 6, 2016
Grant date	Sep 6, 2016

Abstract

The present invention relates to novel 4-pregenen-11β-17-21-triol-3,20-dione derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals, as modulators of glucocorticoid or mineralocorticoid receptors. The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat disorders associated with glucocorticoid or mineralocorticoid receptor modulation.

First claim

What is claimed is:

1. A method of treating a disorder associated with glucocorticoid receptor modulation, which comprises administering to a patient an ophthalmically acceptable pharmaceutical composition comprising a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

2. The method according to claim 1 wherein the disorder associated with glucocorticoid receptor modulation is selected from the group consisting of elevated intraocular pressure, glaucoma, retinal vein occlusions, diabetic retinopathy, various forms of macular edema, post-surgical inflammation, inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, retinal detachment, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitis, corneal injury from chemical, radiation, or thermal burns, penetration of foreign bodies, allergy, or combinations thereof.

3. The method according to claim 1 wherein the disorder associated with glucocorticoid receptor modulation is selected from dry eye, blepharitis, ocular rosacea, meibomian gland dysfunction, uveitis and macular degeneration.

4. The method according to claim 3 wherein the disorder associated with glucocorticoid receptor modulation is dry eye.

5. The method according to claim 1 wherein the ophthalmically acceptable pharmaceutical composition is topically administered.

6. The method according to claim 4 wherein the ophthalmically acceptable pharmaceutical composition is topically administered.

7. The method according to claim 1 wherein the ophthalmically acceptable pharmaceutical composition is formulated for intraocular injection.

8. The method according to claim 4 wherein the ophthalmically acceptable pharmaceutical composition is formulated for intraocular injection.

9. The method according to claim 1 wherein the ophthalmically acceptable pharmaceutical composition is formulated into sustained release or controlled release intraocular implants comprising biodegradable polymers.

10. The method according to claim 4 wherein the ophthalmically acceptable pharmaceutical composition is formulated into sustained release or controlled release intraocular implants comprising biodegradable polymers.

11. The method according to claim 9 , wherein the biodegradable polymer is selected from the group consisting of polylactic acid, plyglycolic acid, and combinations thereof.

12. The method according to claim 10 , wherein the biodegradable polymer is selected from the group consisting of polylactic acid, plyglycolic acid, and combinations thereof.

Assignees

• Allergan Inc

Inventors

• Edelman Jeffrey L
• Nehme Alissar
• Malone Thomas C

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P31/22

  for herpes viruses · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• A61P27/02

  Ophthalmic agents · CPC title